
|Videos|May 5, 2017
Immunotherapy Combinations on the Horizon in Melanoma
Author(s)Jason J. Luke, MD
Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses immunotherapy combinations on the horizon in melanoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































